SATT Aquitaine invests in the maturation of innovative projects from regional public research. SATT Aquitaine’s objective is to mature these inventions, from the stage of research results to pre-industrialization (proof of concept), and to support them until they are brought to market.
Lead by Christophe Grosset, Inserm research director and head of theTeam 06 – MIRCADE, Methods and Innovations for the Research in Pediatric Cancers., the GSTAT project offers a new therapeutic option for the treatment of an incurable solid tumor in children, the infiltrating glioma of the brain stem.
The objective of SATT Aquitaine’s €641,000 investment is to formulate and test the drug candidate in-vitro and in-vivo using the molecules identified during the research team’s work.
More information at this link